139 related articles for article (PubMed ID: 20299377)
1. Timing of erythropoiesis-stimulating agent initiation and adverse outcomes in nondialysis CKD: a propensity-matched observational study.
Seliger S; Fox KM; Gandra SR; Bradbury B; Hsu VD; Walker L; Chiou CF; Fink JC
Clin J Am Soc Nephrol; 2010 May; 5(5):882-8. PubMed ID: 20299377
[TBL] [Abstract][Full Text] [Related]
2. Individualizing decision-making--resurrecting the doctor-patient relationship in the anemia debate.
Agarwal R
Clin J Am Soc Nephrol; 2010 Jul; 5(7):1340-6. PubMed ID: 20448071
[TBL] [Abstract][Full Text] [Related]
3. Transfusion burden among patients with chronic kidney disease and anemia.
Lawler EV; Bradbury BD; Fonda JR; Gaziano JM; Gagnon DR
Clin J Am Soc Nephrol; 2010 Apr; 5(4):667-72. PubMed ID: 20299366
[TBL] [Abstract][Full Text] [Related]
4. It's time to compare anemia management strategies in hemodialysis.
Coyne DW
Clin J Am Soc Nephrol; 2010 Apr; 5(4):740-2. PubMed ID: 20299363
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin stimulating agents and epoetin alfa revisited: what's really relevant?
Walker RG
Clin J Am Soc Nephrol; 2008 Jul; 3(4):935-7. PubMed ID: 18579671
[No Abstract] [Full Text] [Related]
6. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
7. [Regarding the optimal hemoglobin target range in renal anemia].
Maurin N
Med Klin (Munich); 2008 Sep; 103(9):633-7. PubMed ID: 18813886
[TBL] [Abstract][Full Text] [Related]
8. Initiation of anaemia management in patients with chronic kidney disease not on dialysis in the Veterans Health Administration.
Lawler EV; Gagnon DR; Fink J; Seliger S; Fonda J; Do TP; Gaziano JM; Bradbury BD
Nephrol Dial Transplant; 2010 Jul; 25(7):2237-44. PubMed ID: 20083469
[TBL] [Abstract][Full Text] [Related]
9. Triumph and tragedy: anemia management in chronic kidney disease.
Novak JE; Szczech LA
Curr Opin Nephrol Hypertens; 2008 Nov; 17(6):580-8. PubMed ID: 18941350
[TBL] [Abstract][Full Text] [Related]
10. Biosimilar epoetin zeta in nephrology - a single-dialysis center experience.
Lonnemann G; Wrenger E
Clin Nephrol; 2011 Jan; 75(1):59-62. PubMed ID: 21176751
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality of life and hemoglobin levels in chronic kidney disease patients.
Finkelstein FO; Story K; Firanek C; Mendelssohn D; Barre P; Takano T; Soroka S; Mujais S
Clin J Am Soc Nephrol; 2009 Jan; 4(1):33-8. PubMed ID: 18987300
[TBL] [Abstract][Full Text] [Related]
12. Mortality in incident haemodialysis patients: time-dependent haemoglobin levels and erythropoiesis-stimulating agent dose are independent predictive factors in the ANSWER study.
Fort J; Cuevas X; García F; Pérez-García R; Lladós F; Lozano J; Martín-Malo A;
Nephrol Dial Transplant; 2010 Aug; 25(8):2702-10. PubMed ID: 20176608
[TBL] [Abstract][Full Text] [Related]
13. Association of a change in erythropoiesis-stimulating agent dose during hospitalization and subsequent hemoglobin levels and transfusions in hemodialysis patients.
Wong BC; Ravani P; Manns BJ; Lewin A; Zhang X; Chin R; Hemmelgarn BR; Tonelli M; Oliver MJ; Quinn RR
Am J Kidney Dis; 2013 Nov; 62(5):947-52. PubMed ID: 23856380
[TBL] [Abstract][Full Text] [Related]
14. Erythropoiesis-stimulating agent slows the progression of chronic kidney disease: a possibility of a direct action of erythropoietin.
Tsuruya K; Yoshida H; Suehiro T; Fujisaki K; Masutani K; Kitazono T
Ren Fail; 2016; 38(3):390-6. PubMed ID: 26822074
[TBL] [Abstract][Full Text] [Related]
15. Can the response to iron therapy be predicted in anemic nondialysis patients with chronic kidney disease?
Stancu S; Bârsan L; Stanciu A; Mircescu G
Clin J Am Soc Nephrol; 2010 Mar; 5(3):409-16. PubMed ID: 20019121
[TBL] [Abstract][Full Text] [Related]
16. Is the problem with the vehicle or the destination? Does high-dose ESA or high haemoglobin contribute to poor outcomes in CKD?
Badve SV; Hawley CM; Johnson DW
Nephrology (Carlton); 2011 Feb; 16(2):144-53. PubMed ID: 21272125
[TBL] [Abstract][Full Text] [Related]
17. Strategies for successfully managing the anemia of chronic kidney disease in the long-term care setting.
Germain MJ
Consult Pharm; 2008 Mar; 23 Suppl A():11-7. PubMed ID: 18454575
[TBL] [Abstract][Full Text] [Related]
18. Blood transfusion use in non-dialysis-dependent chronic kidney disease patients aged 65 years and older.
Ibrahim HN; Ishani A; Guo H; Gilbertson DT
Nephrol Dial Transplant; 2009 Oct; 24(10):3138-43. PubMed ID: 19451656
[TBL] [Abstract][Full Text] [Related]
19. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level?
Singh AK
Curr Opin Nephrol Hypertens; 2010 Sep; 19(5):420-4. PubMed ID: 20689425
[TBL] [Abstract][Full Text] [Related]
20. The FDA's perspective on the risk for rapid rise in hemoglobin in treating CKD anemia: Quo Vadis.
Singh AK
Clin J Am Soc Nephrol; 2010 Apr; 5(4):553-6. PubMed ID: 20203166
[No Abstract] [Full Text] [Related]
[Next] [New Search]
